University of Pittsburgh researchers have developed a viral vector that allows for the overexpression of Cdkn1a cDNA selectively in cardiomyocytes. This innovation increases cardiomyocyte p21 protein levels, which has been shown to decrease pathological growth in the heart in preclinical murine models of hypertrophic cardiomyopathy. Additionally, this treatment improves diastolic function, offering a promising new approach to managing this genetic heart condition.